COVID-19 Vaccine Update

Delaware Division of Public Health | January 26, 2021 With limited supply of vaccine from the federal government, the state is faced with very difficult decisions about the most effective use of the doses it has. The science shows that the first dose of COVID-19 vaccine provides 52% to 80% protection, so concentrating on first doses is critical to reducing hospitalizations and deaths. We also believe we need to get Phase 1A high-risk health care workers second doses as soon as possible – both because they have frequent contact with COVID patients and have less ability to social distance. Until Read More …

Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EAA

This risk assessment presents the latest available information on the recent emergence of two variants of potential concern, VOC 202012/01 discovered in the United Kingdom (UK) and another variant, 501.V2 identified in South Africa. It also assesses the risk of these variants of concern being introduced and spread in the EU/EEA, as well as the increased impact this would have on health systems in the coming weeks. Read more.

Questions about the COVID-19 Vaccines?

Click below for videos featuring ChristianaCare infection prevention expert and COVID-19 advisor Dr. Marci Drees! What is the COVID Vaccine Approval Process? (video) Have COVID vaccines been tested in minority populations? (video) What are the possible side effects of the COVID vaccine? (video) What are COVID-19 mRNA vaccines? (video) Can you get COVID-19 twice? (video) What is Herd Immunity? (video)

7 Looming Questions About the Rollout of a COVID-19 Vaccine

Helen Branswell & Ed Silverman | STAT News | October 9, 2020 The race to develop Covid-19 vaccines could well see some Americans vaccinated before the end of 2020 — less than a year after the world first learned a new virus was causing a dangerous new form of pneumonia in China. The design, testing, and mass production of multiple vaccines has never been attempted on this type of timeline, making this moment a turning point in the development of vaccines to respond to new disease threats. But the complexity of that work may pale in comparison to what comes Read More …